GREY:ICOTF - Post by User
Post by
GoldenHawkon Jul 12, 2018 12:27pm
104 Views
Post# 28306835
From the last news release
From the last news releaseNews is possibly hours away and everyone knows it especially the ones building the FAKE ASK walls so you sell them your shares for cheap! .30s .40s .50s and more, here we come!
“We are pleased to report a positive primary end point related to our 32-subject phase 1 clinical study," stated Andrew Rae, president and chief executive officer of iCo Therapeutics. "No patients experienced drug-related adverse or serious adverse events in our phase 1 clinical study and we believe this allows us to claim leadership in the race towards developing an oral amphotericin B drug." Mr. Rae also stated, "iCo management waits with anticipation We are pleased to report a positive primary end point related to our 32-subject phase 1 clinical study," stated Andrew Rae, president and chief executive officer of iCo Therapeutics. "No patients experienced drug-related adverse or serious adverse events in our phase 1 clinical study and we believe this allows us to claim leadership in the race towards developing an oral amphotericin B drug." Mr. Rae also stated, "iCo management waits with anticipation important and material pharmacokinetic data in the coming weeks."
The above was released weeks ago so news and results are anytime now!